GlassScriptPhysician profile
James L Hunt
NPI 1043279029
$16,869.16
in general payments reported to CMS, 2019-2025
37 companies · $24.47 in 2025
The $24.47 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $283 · 2022: $77.81 · 2023: $754 · 2024: $14K · 2025: $24.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,100.00 |
| Food and Beverage | $1,160.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $14,100.00 | 2024 | |
| Novo Nordisk INC | $645.94 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $342.02 | 2019-2023 | |
| Glaxosmithkline, LLC. | $206.04 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.54 | 2019-2023 | Tradjenta, Jardiance, Ofev |
| Abbvie INC. | $147.70 | 2023-2024 | |
| Amgen INC. | $109.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $96.21 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $85.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $84.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $81.96 | 2019-2020 | |
| Astellas Pharma US INC | $80.06 | 2019-2024 | Veozah |
| Lilly USA, LLC | $57.03 | 2019-2024 | Mounjaro |
| Sanofi Pasteur INC. | $51.23 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $49.44 | 2020-2023 | Eliquis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $48.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.68 | 2023 | |
| Dexcom, INC. | $38.22 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $36.89 | 2019-2024 | |
| Shire North American Group INC | $29.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.91 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $27.58 | 2023 | Rexulti |
| Organon LLC | $27.03 | 2023 | Nexplanon |
| Allergan, INC. | $24.49 | 2019 | |
| Radius Health, INC. | $24.47 | 2025 | Tymlos |
| Lundbeck LLC | $24.18 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $23.69 | 2019 | |
| Abbott Laboratories | $22.87 | 2019 | |
| Axsome Therapeutics, INC. | $22.83 | 2023 | Auvelity |
| Vertex Pharmaceuticals Incorporated | $20.27 | 2024 | |
| Celgene Corporation | $20.14 | 2019 | |
| Boston Scientific Corporation | $16.58 | 2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $16.17 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $14.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2019 | |
| Gilead Sciences, INC. | $13.02 | 2020 | |
| Circassia INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.